[1]
|
Tan, W.L., Jain, A., Takano, A., et al. (2016) Novel Therapeutic Targets on the Horizon for Lung Cancer. The Lancet Oncology, 17, e347-e362. https://doi.org/10.1016/S1470-2045(16)30123-1
|
[2]
|
Mamdani, H., Matosevic, S., Kha-lid, A.B., Durm, G. and Jalal, S.I. (2022) Immunotherapy in Lung Cancer: Current Landscape and Future Directions. Frontiers in Immunology, 13, 823618. https://doi.org/10.3389/fimmu.2022.823618
|
[3]
|
Fiorica, F., Belluomini, L., Stefanelli, A., Santini, A., Urbini, B., Giorgi, C. and Frassoldati, A. (2018) Immune Checkpoint Inhibitor Nivolumab and Radiotherapy in Pretreated Lung Cancer Patients: Efficacy and Safety of Combination. American Journal of Clinical On-cology, 41, 1101-1105. https://doi.org/10.1097/COC.0000000000000428
|
[4]
|
Bassanelli, M., Ricciuti, B., Giannarelli, D., Cecere, F.L., Roberto, M., Giacinti, S., Barucca, V., Santarelli, M., Ruggeri, E.M., Marchetti, P., Cognet-ti, F., Gelibter, A., Cortesi, E., Chiari, R., Milella, M. and Ceribelli, A. (2021) Systemic Effect of Radiotherapy before or after Nivolumab in Lung Cancer: An Observational, Retrospective, Multicenter Study. Tumori Journal, 108, 250-257. https://doi.org/10.1177/03008916211004733
|
[5]
|
Borghaei, H., Gettinger, S., Vokes, E.E., Chow, L.Q.M., Burgio, M.A., de Castro Carpeno, J., Pluzanski, A., Arrieta, O., Frontera, O.A., Chiari, R., Butts, C., Wójcik-Tomaszewska, J., Coudert, B., Garassino, M.C., Ready, N., Felip, E., García, M.A., Waterhouse, D., Domine, M., Barlesi, F., Antonia, S., Wohlleber, M., Gerber, D.E., Czyzewicz, G., Spigel, D.R., Crino, L., Eberhardt, W.E.E., Li, A., Marimuthu, S. and Brahmer, J. (2021) Five-Year Outcomes from the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 39, 723-733. https://doi.org/10.1200/JCO.20.01605
|
[6]
|
Anouti, B., Althouse, S., Durm, G. and Hanna, N. (2020) Prognostic Variables Associated with Improved Outcomes in Patients with Stage III NSCLC Treated with Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study from the Hoosier Cancer Research Network LUN 14-179. Clinical Lung Cancer, 21, 288-293. https://doi.org/10.1016/j.cllc.2019.06.009
|
[7]
|
Gadgeel, S., Rodríguez-Abreu, D., Speranza, G., Esteban, E., Felip, E., Dómine, M., Hui, R., Hochmair, M.J., Clingan, P., Powell, S.F., Cheng, S.Y., Bischoff, H.G., Peled, N., Grossi, F., Jennens, R.R., Reck, M., Garon, E.B., Novello, S., Ru-bio-Viqueira, B., Boyer, M., Kurata, T., Gray, J.E., Yang, J., Bas, T., Pietanza, M.C. and Garassino, M.C. (2020) Up-dated Analysis from KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreat-ed Metastatic Nonsquamous Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 38, 1505-1517.
https://doi.org/10.1200/JCO.19.03136
|
[8]
|
Reck, M., Rodríguez-Abreu, D., Robinson, A.G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., O’Brien, M., Rao, S., Hotta, K., Vandormael, K., Riccio, A., Yang, J., Pietanza, M.C. and Brahmer, J.R. (2019) Updated Analysis of KEYNOTE-024: Pembrolizumab versus Plati-num-Based Chemotherapy for Advanced Non- Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. Journal of Clinical Oncology, 37, 537-546. https://doi.org/10.1200/JCO.18.00149
|
[9]
|
Mok, T.S.K., Wu, Y.L., Kudaba, I., Kowalski, D.M., Cho, B.C., Turna, H.Z., Castro Jr., G., Srimuninnimit, V., Laktionov, K.K., Bondarenko, I., Kubota, K., Lubiniecki, G.M., Zhang, J., Kush, D. and Lopes, G. (2019) KEYNOTE-042 Investigators. Pembrolizumab versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial. The Lancet, 393, 1819-1830. https://doi.org/10.1016/S0140-6736(18)32409-7
|
[10]
|
Reck, M., Rodríguez-Abreu, D., Robinson, A.G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., O’Brien, M., Rao, S., Hotta, K., Leiby, M.A., Lubiniecki, G.M., Shentu, Y., Rangwala, R. and Brahmer, J.R. (2016) KEYNOTE-024 Investigators. Pembroli-zumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 375, 1823-1833. https://doi.org/10.1056/NEJMoa1606774
|
[11]
|
Nishio, M., Barlesi, F., West, H., Ball, S., Bordoni, R., Cobo, M., Longeras, P.D., Goldschmidt Jr., J., Novello, S., Orlandi, F., Sanborn, R.E., Szalai, Z., Ursol, G., Mendus, D., Wang, L., Wen, X., McCleland, M., Hoang, T., Phan, S. and Socinski, M.A. (2021) Atezolizumab Plus Chemother-apy for First-Line Treatment of Nonsquamous NSCLC: Results from the Randomized Phase 3 IMpower132 Trial. Jour-nal of Thoracic Oncology, 16, 653-664.
https://doi.org/10.1016/j.jtho.2020.11.025
|
[12]
|
Socinski, M.A., Özgüroğlu, M., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Gray, J.E., Park, K., Vincent, M., Mann, H., Newton, M., Dennis, P.A. and Antonia, S.J. (2021) Durvalumab after Concurrent Chemoradiotherapy in Elderly Patients with Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC). Clinical Lung Cancer, 22, 549-561. https://doi.org/10.1016/j.cllc.2021.05.009
|
[13]
|
Inoue, H., Ono, A., Kawabata, T., Mamesaya, N., Kawamura, T., Kobayashi, H., Omori, S., Wakuda, K., Kenmotsu, H., Naito, T., Murakami, H., Yasui, K., Ogawa, H., Onoe, T., Endo, M., Harada, H. and Takahashi, T. (2020) Clinical and Radia-tion Dose-Volume Factors Related to Pneumonitis after Treatment with Radiation and Durvalumab in Locally Advanced Non-Small Cell Lung Cancer. Investigational New Drugs, 38, 1612-1617.
https://doi.org/10.1007/s10637-020-00917-2
|
[14]
|
Hellmann, M.D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.W., Carcereny Costa, E., Park, K., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., Sakai, H., Albert, I., Vergnenegre, A., Peters, S., Syrigos, K., Barlesi, F., Reck, M., Borghaei, H., Brahmer, J.R., O’Byrne, K.J., Geese, W.J., Bhagavatheeswaran, P., Rabindran, S.K., Kasinathan, R.S., Nathan, F.E. and Ramalingam, S.S. (2019) Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 381, 2020-2031. https://doi.org/10.1056/NEJMoa1910231
|
[15]
|
Reck, M., Ciuleanu, T.-E., Dols, M.C., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E. and Juan-Vidal, O. (2020) Nivolumab (NIVO)+ Ipilimumab (IPI)+ 2 Cycles of Platinum-Doublet Chemotherapy (Chemo) vs 4 Cycles Chemo as First-Line (1L) Treatment (tx) for Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC): CheckMate 9LA. Journal of Clinical Oncology, 38, 9501-9501.
https://doi.org/10.1200/JCO.2020.38.15_suppl.9501
|